Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C.

Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098.

2.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C.

Oncotarget. 2016 May 31;7(22):32532-42. doi: 10.18632/oncotarget.8687.

3.

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC.

Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19.

4.

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, Rojo F, Routier E, Guarin E, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Soria JC.

Clin Cancer Res. 2012 Sep 1;18(17):4806-19. Epub 2012 Jul 3.

5.

Functional expression of mammalian bitter taste receptors in Caenorhabditis elegans.

Conte C, Guarin E, Marcuz A, Andres-Barquin PJ.

Biochimie. 2006 Jul;88(7):801-6. Epub 2006 Feb 9.

PMID:
16494987
6.

Functional expression of a mammalian olfactory receptor in Caenorhabditis elegans.

Milani N, Guarin E, Renfer E, Nef P, Andres-Barquin PJ.

Neuroreport. 2002 Dec 20;13(18):2515-20.

PMID:
12499859
7.

Ca2+ signaling via the neuronal calcium sensor-1 regulates associative learning and memory in C. elegans.

Gomez M, De Castro E, Guarin E, Sasakura H, Kuhara A, Mori I, Bartfai T, Bargmann CI, Nef P.

Neuron. 2001 Apr;30(1):241-8.

8.

Cell death is prevented in thalamic fields but not in injured neocortical areas after permanent focal ischaemia in mice overexpressing the anti-apoptotic protein Bcl-2.

De Bilbao F, Guarin E, Nef P, Vallet P, Giannakopoulos P, Dubois-Dauphin M.

Eur J Neurosci. 2000 Mar;12(3):921-34.

PMID:
10762322
9.

Postnatal distribution of cpp32/caspase 3 mRNA in the mouse central nervous system: an in situ hybridization study.

de Bilbao F, Guarin E, Nef P, Vallet P, Giannakopoulos P, Dubois-Dauphin M.

J Comp Neurol. 1999 Jul 5;409(3):339-57.

PMID:
10379822
10.

The mouse cpp32 mRNA transcript is early up-regulated in axotomized motoneurons following facial nerve transection.

de Bilbao F, Guarin E, Nef P, Dubois-Dauphin M.

Neurosci Lett. 1999 Apr 30;266(1):65-8.

PMID:
10336185
11.

cpp32 messenger RNA neosynthesis is induced by fatal axotomy and is not regulated by athanatal Bcl-2 over-expression.

Guarin E, Seuret P, Nef S, de Bilbao F, Nef P, Dubois-Dauphin M.

Neuroscience. 1999 May;90(2):653-64.

PMID:
10215167

Supplemental Content

Loading ...
Support Center